论文部分内容阅读
目的:探讨超声监测卵泡及子宫内膜在不孕症治疗中的临床意义。方法:选取2011年1月-2013年1月东莞市第三民医院收治的98例不孕症患者不孕症作为研究对象,按照入院顺序分为对照组和观察组,每组49例。两组均给予克罗米芬口服以及人类绝经期促性腺激素(HMG)和人绒毛膜促性腺激素(HCG)肌注治疗,治疗时间均为3个月。观察组采用基础体温和尿中雌激素半定量检查来指导HMG和HCG的使用时机和药物调整,对照组采用超声监测卵泡和子宫内膜厚度来指导HMG和HCG的使用时机和药物调整。治疗结束后,采用超声诊断仪统计两组卵泡直径和子宫内膜厚度,并统计两组妊娠率以及卵巢过度刺激综合征(OHSS)的发生率。结果:观察组妊娠率显著高于对照组,OHSS率显著低于对照组,差异有统计学意义(χ2=5.681,P<0.05;χ2=4.404,P<0.05)。卵巢直径和子宫内膜厚度显著高于对照组,差异有统计学意义(t=11.504,P<0.01;t=9.658,P<0.01)。结论:对于不孕症女性来说,在治疗期间给予超声监测,对于提高用药的合理性以及把握用药时机具有重要意义,体现了临床治疗和检验的融合,值得临床考虑。
Objective: To investigate the clinical significance of ultrasonic monitoring of follicles and endometrium in the treatment of infertility. Methods: From January 2011 to January 2013, Dongguan Third People’s Hospital admitted 98 cases of infertility patients as the research object, according to the order of admission was divided into control group and observation group, 49 cases in each group. Both groups were given clomiphene citrate and human intramuscular gonadotropin (HMG) and human chorionic gonadotropin (HCG) intramuscularly for 3 months. The observation group used the basal body temperature and urinary estrogen semiquantitative examination to guide the use of HMG and HCG timing and drug adjustment, the control group using ultrasound to monitor follicular and endometrial thickness to guide the use of HMG and HCG timing and drug adjustment. After the treatment, the diameter of the follicles and the thickness of the endometrium of the two groups were calculated by using the ultrasonic diagnostic apparatus. The pregnancy rates and the incidence of ovarian hyperstimulation syndrome (OHSS) were also calculated. Results: The pregnancy rate in the observation group was significantly higher than that in the control group. The OHSS rate in the observation group was significantly lower than that in the control group (χ2 = 5.681, P <0.05; χ2 = 4.404, P <0.05). Ovarian diameter and endometrial thickness were significantly higher than the control group, the difference was statistically significant (t = 11.504, P <0.01; t = 9.658, P <0.01). Conclusion: For women with infertility, ultrasound monitoring during treatment is of great significance to improve the rationality of medication and grasp the timing of medication, which reflects the fusion of clinical treatment and test, which deserves clinical consideration.